We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Pavlos Msaouel

Pavlos Msaouel MD, PhD

Chief Hematology/Oncology Fellow, University of Texas MD Anderson Cancer Center, Houston, TX

Dr. Pavlos Msaouel completed his MD/PhD studies with highest honors at the medical school of the University of Athens focusing on neoplasm research, and was a research fellow at Mayo Clinic working on oncolytic virotherapy. He then completed his internal medicine residency training at the Albert Einstein College of Medicine / Jacobi Medical Center, where he was each year awarded a best teaching or overall housestaff award, and additionally served as Chief Resident for the program. He is currently the Chief Hematology/Oncology Fellow at the University of Texas MD Anderson Cancer Center. During his first year of fellowship, he was awarded the Clifton D. Howe Award for Clinical Excellence, subsequently selected to his fellowship's T32 research training program, and further awarded the William L. Pippin, Jr Endowed Fellowship in Genitourinary Research. His translational cancer research in rare kidney malignancies is additionally supported by a 2017 Young Investigator Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology. He is the co-primary investigator of three ongoing clinical trials of novel therapeutic strategies against common and rare variants of renal cell carcinomas. His research focuses on identifying and targeting biological drivers of renal cell carcinomas, with a major interest in renal medullary carcinoma – a highly aggressive renal cell carcinoma that predominantly afflicts young African Americans with sickle cell trait.